FDA Regulatory Status & Compounding Considerations
This page explains the federal regulatory framework relevant to substances discussed across Phoenix Meds category pages and describes what Phoenix Meds does and does not conclude from the public FDA record.
The substances discussed on this site do not all have the same regulatory status. Some are approved or licensed products, some appear in FDA interim compounding-policy materials, and for others we have not identified an applicable basis under sections 503A or 503B for the preparations discussed on their respective category pages.
This page is regulatory-tracking information drawn from public FDA materials. It is not medical advice, legal advice, or a determination that a particular product, prescription, preparation or transaction is lawful.
Educational and Regulatory Reference
The information on this page is intended for licensed healthcare facilities and professionals reviewing the federal regulatory record.
Nothing on this page:
- recommends use of a particular substance;
- establishes that a preparation is safe or effective;
- establishes that a particular preparation qualifies for compounding;
- replaces review by the responsible pharmacy, prescriber or qualified legal or regulatory counsel; or
- should be read as extending the regulatory status of one substance to another.
The exact substance, formulation, route of administration, facility and statutory framework all matter.
Current Federal Regulatory Position — September 2026
Licensed Biological Products
Some products discussed on this site are FDA-approved products that became licensed biological products.
Somatropin products and tesamorelin are examples.
FDA states that biological products subject to licensure under section 351 of the Public Health Service Act are not eligible for the compounded-drug exemptions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
That is different from saying those products are unapproved. Their regulatory issue is that the ordinary 503A and 503B compounded-drug exemptions do not apply to them.
Somatropin is also subject to separate federal requirements specifically applicable to human growth hormone. Those requirements are addressed on our Growth Hormone & Related Peptides category page.
Substances in FDA Category 1 Materials
FDA maintains interim policies for certain bulk drug substances that have been nominated while the agency evaluates whether they should be included on a statutory Bulks List. Category 1 is not FDA approval. Category 1 is also not inclusion on the 503A or 503B Bulks List. It describes an interim FDA enforcement position that applies only when the conditions stated in the applicable FDA guidance are met.
Examples relevant to this site include:
GHK-Cu, except for injectable routes of administration: FDA’s May 14, 2026 503A nominations document places non-injectable GHK-Cu in Category 1. Injectable GHK-Cu is expressly outside that entry.
Sermorelin acetate: FDA’s 503B nominations materials place sermorelin acetate in Category 1. Its prior approved-drug history and the other statutory requirements still have to be considered separately for a particular preparation.
A Category 1 entry should therefore never be described on this site as FDA approval, inclusion on a Bulks List or automatic authority to compound.
Substances in FDA Category 2 Materials
Category 2 is materially different.
FDA uses Category 2 for nominated bulk drug substances for which it has identified significant safety risks during evaluation. FDA does not apply its Category 1 interim enforcement policy to these substances.
Ipamorelin acetate appears in Category 2 of FDA’s 503B materials.
A Category 2 entry reflects FDA’s identification of significant safety risks relating to use of the substance in compounding while FDA continues its evaluation. Category 2 should not be described as FDA approval, authorization, inclusion on a Bulks List, or a compounding pathway.
Substances for Which We Did Not Identify an Applicable 503A or 503B Basis
For several preparations discussed on Phoenix Meds category pages, our September 2026 review did not identify an applicable federal basis under section 503A or section 503B for compounding from bulk drug substance.
Examples include the preparations discussed on our pages for: BPC-157; KPV; TB-500; Semax; Selank; and injectable GHK-Cu.
Those are dated findings from the federal sources reviewed. They are not universal legal conclusions about every possible factual situation.
The individual category pages explain the substance-specific record and should be read rather than assuming that one peptide’s position applies to another.
Why Phoenix Meds Does Not Use One Generic “Peptide Status”
Peptide is a scientific description, not a regulatory category that determines legal status.
Two substances that appear together in a clinic protocol or supplier catalogue may occupy completely different positions in FDA’s regulatory framework.
The relevant questions can include:
whether the substance is a drug or licensed biological product;
whether an applicable USP or NF monograph exists;
whether it is a component of an FDA-approved drug product;
whether it appears on the applicable Bulks List;
whether an FDA interim policy applies;
whether FDA has identified significant safety risks;
the route of administration;
and the statutory framework being relied upon.
Phoenix Meds therefore reviews substances individually rather than assigning one conclusion to an entire class.
Understanding Section 503A
Section 503A applies to qualifying pharmacy compounding by state-licensed pharmacists or physicians when the statutory conditions are met.
When compounding from a bulk drug substance, FDA explains that the bulk substance must:
comply with an applicable United States Pharmacopeia or National Formulary monograph, if one exists;
if no applicable monograph exists, be a component of an FDA-approved drug product; or
if neither of those conditions applies, appear on the 503A Bulks List.
Bulk drug substances used under section 503A must also be accompanied by a valid Certificate of Analysis and manufactured by an establishment registered with FDA under section 510.
Those requirements are separate.
A Certificate of Analysis does not establish that the substance satisfies the statutory bulk-substance condition.
Likewise, a state pharmacy license establishes information about the facility. It does not by itself establish that a particular bulk drug substance qualifies for use in compounding.
Section 503A generally involves compounding for an identified individual patient, subject to the statute’s provisions concerning limited anticipatory compounding.
FDA's 503A Interim Policy
FDA also maintains an interim policy for certain substances nominated for the 503A Bulks List while the agency evaluates them. The categories should not be confused with the Bulks List itself.
Category 1
Category 1 contains substances under evaluation that FDA has not placed in another category. FDA states that it does not intend to take action against a compounder for using a Category 1 substance when the conditions described in its guidance are satisfied. That is an enforcement policy. It is not FDA approval and it is not inclusion on the 503A Bulks List.
Category 2
Category 2 contains substances for which FDA has identified significant safety risks during evaluation. FDA states that its Category 1 enforcement policy does not apply to these substances.
Category 3
Category 3 concerns substances that were nominated without enough supporting information for FDA to evaluate them under the interim framework. A category entry should always be read together with the current FDA document and guidance rather than treated as permanent regulatory status.
Understanding Section 503B
Section 503B applies to FDA-registered outsourcing facilities and uses a different framework from section 503A.
The 503A bulk-substance criteria should not be copied over to section 503B.
For a drug compounded from a bulk drug substance to qualify under section 503B, the applicable bulk-substance conditions must be satisfied. FDA explains that an outsourcing facility generally may not compound from a bulk drug substance unless:
- the bulk drug substance appears on the 503B Bulks List identifying substances for which FDA has determined there is a clinical need; or
- the drug product compounded from that bulk substance appears on FDA’s drug-shortage list at the time of compounding, distribution and dispensing.
Bulk drug substances used under section 503B must also be accompanied by a valid Certificate of Analysis and manufactured by an establishment registered with FDA under section 510.
If an applicable monograph exists under the United States Pharmacopeia (USP), National Formulary (NF), or another compendium or pharmacopeia recognized by the Secretary, the bulk drug substance must comply with that monograph.
Registration as a 503B outsourcing facility does not by itself establish that every substance or preparation compounded by the facility qualifies under section 503B.
Facility status and product-specific eligibility are separate questions.
FDA's 503B Interim Policy
Category 1
identifies substances that remain under evaluation and may fall within FDA’s interim enforcement policy when all stated conditions are met.Category 2
identifies substances for which FDA has identified significant safety risks and to which the Category 1 enforcement policy does not apply.Category 3
identifies substances that were nominated without adequate supporting information for FDA to evaluate them.FDA revised this policy in January 2025 and does not intend to assign new nominations submitted on or after January 7, 2025 to these categories. Existing Category 1 substances may remain within the interim policy while FDA continues its evaluation. Again, an interim category is not the same thing as inclusion on the final 503B Bulks List.
FDA-Approved and Licensed Products Require Separate Analysis
An FDA-approved or licensed product should not be grouped automatically with an unapproved bulk drug substance.
Approval can change which federal rules apply.
For example, FDA states that biological products subject to licensure under section 351 of the Public Health Service Act are not eligible for the compounded-drug exemptions in sections 503A and 503B.
Somatropin and tesamorelin therefore require a different analysis from substances such as BPC-157 or Semax.
Likewise, the existence or prior existence of an approved drug product can be relevant to the bulk-substance analysis for some drugs.
The correct approach is substance-specific rather than category-wide.
2026 Regulatory Developments
April and May 2026 — GHK-Cu
FDA’s 503A nominations materials record a change involving GHK-Cu.
GHK-Cu was removed from Category 1 in April 2026 after nominations were withdrawn.
FDA subsequently recorded that a nominator clarified that it intended to withdraw only the injectable route.
FDA’s May 14, 2026 document lists:
GHK-Cu, except for injectable routes of administration
in Category 1.
Injectable GHK-Cu therefore falls outside that Category 1 entry.
FDA has also stated that it intends further advisory committee consultation concerning GHK-Cu.
June 17, 2026 — Wholesale Peptide Warning Letter
FDA issued a warning letter to Wholesale Peptide after reviewing statements on the firm’s website. The products at issue carried language including “Research Use Only” and “not for human consumption.” FDA nevertheless concluded from the firm’s promotional statements and other labeling that the products were intended as human drugs. The warning letter concerned that company and the particular products FDA reviewed. It should not be described as a ruling automatically establishing violations by every peptide distributor or every clinic. The broader regulatory point is that a disclaimer printed on a product does not necessarily determine FDA’s view of intended use when surrounding promotion and distribution evidence points to human-drug use.“Research Use Only” Does Not Determine Regulatory Status
Phoenix Meds does not treat “Research Use Only,” “RUO,” or “Not for Human Consumption” language as establishing a regulatory pathway.
Such language does not:
place a substance on the 503A or 503B Bulks List;
create an FDA approval;
place a substance within Category 1;
establish eligibility under section 503A or 503B; or
by itself determine FDA’s assessment of intended use.
FDA may evaluate intended use from the circumstances surrounding labeling, promotion and distribution.
A regulatory analysis therefore has to look beyond the words printed on the vial or website.
FDA convened the Pharmacy Compounding Advisory Committee in July 2026 to discuss several nominated bulk drug substances being considered for possible inclusion on the 503A Bulks List.
On July 23, the substances included:
BPC-157 free base and acetate;
KPV free base and acetate;
TB-500 free base and acetate; and
MOTS-C free base and acetate.
On July 24, the substances included:
Emideltide/DSIP free base and acetate;
Semax free base and acetate; and
Epitalon free base and acetate.
The uses FDA evaluated were substance-specific.
For example:
BPC-157 was evaluated for ulcerative colitis;
KPV for wound healing and inflammatory conditions;
TB-500 for wound healing;
MOTS-C for obesity and osteoporosis;
Semax for cerebral ischemia, migraine and trigeminal neuralgia;
and Epitalon for insomnia.
These proceedings were advisory.
A Pharmacy Compounding Advisory Committee recommendation does not itself amend the 503A Bulks List and does not itself create FDA approval or statutory authority to compound a substance.
As of our September 2026 review, these July proceedings had not themselves changed the codified 503A Bulks List.
Reading Advisory Committee Proceedings Correctly
FDA Staff Evaluation
FDA prepares scientific and regulatory materials describing its evaluation of a nominated substance.Advisory Committee Recommendation
The Pharmacy Compounding Advisory Committee provides advice to FDA. Its recommendation is not binding on the agency.Formal Regulatory Action
Changes to the 503A Bulks List require the formal regulatory process. Until the regulatory record changes, an advisory committee recommendation should be described as a recommendation rather than as FDA approval, clearance or authorization.Phoenix Meds therefore does not describe a favorable advisory vote as meaning that a substance is “FDA approved,” “FDA cleared,” or automatically eligible for compounding.
Substance-Specific Examples
BPC-157
FDA evaluated BPC-157-related bulk drug substances during the July 2026 advisory proceedings for ulcerative colitis. Based on the federal sources reviewed in September 2026, Phoenix Meds did not identify an applicable 503A or 503B basis for compounding BPC-157 from bulk drug substance. The July advisory proceedings did not themselves add BPC-157 to the 503A Bulks List.KPV
FDA evaluated KPV-related bulk drug substances during the July 2026 advisory proceedings for wound healing and inflammatory conditions. Based on the federal sources reviewed in September 2026, Phoenix Meds did not identify an applicable 503A or 503B basis for compounding KPV from bulk drug substance.
TB-500
FDA evaluated TB-500-related bulk drug substances for wound healing during the July 2026 advisory proceedings. Based on the federal sources reviewed in September 2026, Phoenix Meds did not identify an applicable 503A or 503B basis for compounding TB-500 from bulk drug substance.Semax
FDA evaluated Semax free base and Semax acetate during the July 2026 advisory proceedings for cerebral ischemia, migraine and trigeminal neuralgia. Those proceedings should not be described as an FDA evaluation of general cognitive enhancement, focus, mood or stress. Based on the federal sources reviewed in September 2026, Phoenix Meds did not identify an applicable 503A or 503B basis for compounding Semax from bulk drug substance.
Selank
Selank was not one of the substances reviewed during FDA’s July 2026 Pharmacy Compounding Advisory Committee meeting. Based on the federal sources reviewed in September 2026, Phoenix Meds did not identify an applicable 503A or 503B basis for compounding Selank from bulk drug substance.GHK-Cu
FDA’s May 14, 2026 503A nominations document lists: GHK-Cu, except for injectable routes of administration in Category 1.Injectable GHK-Cu is outside that Category 1 entry. Based on the federal sources reviewed in September 2026, Phoenix Meds did not identify an applicable 503A or 503B basis for compounding injectable GHK-Cu from bulk drug substance. Category 1 for non-injectable GHK-Cu should not be described as FDA approval or inclusion on the 503A Bulks List.
Sermorelin Acetate
Sermorelin acetate appears in FDA’s 503B Category 1 materials. Its Category 1 placement reflects an interim FDA enforcement position subject to the applicable policy conditions. It does not establish that every proposed sermorelin preparation satisfies all requirements that may apply.
Ipamorelin Acetate
Ipamorelin acetate appears in Category 2 of FDA’s 503B nominations materials. FDA uses Category 2 for substances for which it has identified significant safety risks during evaluation. Category 2 does not carry the Category 1 interim enforcement policy.
Somatropin and Tesamorelin
Somatropin and tesamorelin are licensed biological products. FDA states that biological products subject to licensure under section 351 of the Public Health Service Act are not eligible for the compounded-drug exemptions under sections 503A and 503B. They therefore should not be analyzed as though they were ordinary nominated bulk drug substances. For somatropin, separate federal human-growth-hormone restrictions also apply.
Category Pages Control the Substance-Specific Analysis
This page explains the framework.
It is not intended to replace the more detailed substance-specific review contained on the relevant Phoenix Meds category page.
Those pages record:
the exact substance reviewed;
the FDA source and date;
any route-specific distinction;
the applicable nomination or Bulks List record;
any relevant FDA-approved product history;
and Phoenix Meds’ dated finding from those sources.
A statement on one category page should not be carried over to a different substance without checking that substance’s own federal record.
Phoenix Meds Inc.'s Role
Phoenix Meds Inc. is not a pharmacy, outsourcing facility, clinic, prescriber, medical provider or law firm.
We do not provide medical or legal advice.
We do not determine whether a particular prescription, preparation or transaction is lawful.
Our regulatory-support role is to:
review public FDA records;
identify the regulatory framework relevant to the substance being discussed;
document what those sources establish on the date reviewed;
distinguish facility credentials from product-specific regulatory status; and
organize regulatory information so that licensed clinics, pharmacies and qualified advisers can conduct their own assessment.
A pharmacy license, FDA outsourcing-facility registration, supplier statement or Certificate of Analysis does not by itself establish the regulatory status of a particular preparation.
Where Phoenix Meds participates in administrative coordination between independently licensed parties, the responsible pharmacy and clinic remain responsible for their own legal, regulatory and clinical determinations.
Independent Review Before Reliance
Red Flags in Regulatory Claims
The following statements should not be accepted without checking the underlying FDA record:
“FDA approved this peptide.”
“The advisory committee vote made it legal.”
“Category 1 means FDA approved.”
“The pharmacy is licensed, so the product is authorized.”
“The facility is registered under 503B, so it can compound any substance.”
“A Certificate of Analysis establishes compounding eligibility.”
“Research Use Only labeling makes clinical distribution permissible.”
“Removal from Category 2 means the substance was cleared.”
“A foreign approval creates a United States compounding pathway.”
“One peptide’s regulatory status applies to a combination or another peptide.”
The underlying FDA record should identify what actually changed, which substance it concerned, what route or use was evaluated and what statutory framework applies.
Official FDA Sources Used for This Review
Disclaimer and Regulatory Scope:
This page provides regulatory information compiled from public FDA materials for licensed healthcare facilities and professionals. It is not medical advice, legal advice, a treatment recommendation, or a determination that any particular substance, preparation, prescription or transaction is lawful.
Phoenix Meds does not represent FDA approval, FDA registration, a pharmacy license, Category 1 placement, advisory committee proceedings or a Certificate of Analysis as establishing that a particular preparation may lawfully be compounded or supplied. Regulatory findings on this page are dated to the sources reviewed and may change as FDA updates its Bulks Lists, interim policies, nomination documents, safety information, guidance or regulations.
State requirements apply in addition to the federal framework discussed here. Clinics, pharmacies and other licensed parties should independently evaluate the requirements that apply to their own activities with qualified professional advisers. Last reviewed: September 2026.